What is HC Wainwright’s Forecast for CMPS Q1 Earnings?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Compass Pathways in a report released on Wednesday, March 25th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.18) EPS and Q4 2027 earnings at ($0.08) EPS.

A number of other research analysts have also weighed in on the company. Canaccord Genuity Group reduced their price target on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Morgan Stanley decreased their price target on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Compass Point set a $15.00 price target on Compass Pathways in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.63.

Compass Pathways Stock Up 0.4%

CMPS stock opened at $5.64 on Thursday. The company has a 50 day moving average price of $6.70 and a two-hundred day moving average price of $6.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 0.77. The stock has a market capitalization of $541.55 million, a P/E ratio of -1.83 and a beta of 1.90. Compass Pathways has a one year low of $2.25 and a one year high of $8.90.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.59).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP increased its position in shares of Compass Pathways by 0.6% in the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after acquiring an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after acquiring an additional 1,350,698 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after acquiring an additional 774,090 shares in the last quarter. Toronto Dominion Bank boosted its position in Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after purchasing an additional 1,529,013 shares during the period. Finally, ARK Investment Management LLC boosted its position in Compass Pathways by 1.6% during the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after purchasing an additional 34,894 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $70 price target and published quarterly EPS estimates for 2027 (Q1 -$0.42, Q2 -$0.27, Q3 -$0.18, Q4 -$0.08), signaling strong analyst conviction that value will increase despite near-term losses. Read More.
• Neutral Sentiment: Media coverage discusses the upcoming FDA review meeting for COMP360 (Compass’s psilocybin therapy candidate). The meeting outcome is uncertain — it could be a major catalyst if favorable, or introduce volatility if concerns are raised. Read More.
• Negative Sentiment: Canaccord cut its price target from $20 to $18 (still a “Buy”), a downgrade in expectations that may weigh on sentiment despite the maintained rating. Read More.
• Negative Sentiment: Morgan Stanley lowered its target from $18 to $16 but kept an “Overweight” rating; another target trim that may pressure short-term sentiment even though the firm remains constructive. Read More. Read More.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.